{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:09:31Z","timestamp":1778602171690,"version":"3.51.4"},"reference-count":15,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"unspecified","delay-in-days":98,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012295","name":"NIHR Newcastle Biomedical Research Centre","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BDR programme","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Newcastle University Research Scholarship","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W000229\/1"],"award-info":[{"award-number":["MR\/W000229\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,3,17]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiotensin receptor blockers (ARB) may be associated with a lower risk of a clinical dementia diagnosis. This study investigated the association between ARB use during life and postmortem dementia neuropathology, compared with angiotensin-converting enzyme inhibitors (ACEI) use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Cases with documented ACEI (n=257) or ARB (n=102) use, regardless of dementia pathology, were selected from the UK Brain Banks Network dataset. Pathology was categorised as either \u2018significant\u2019 pathology (Thal amyloid phase &gt;3, Braak neurofibrillary tangle stage &gt;3, Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD) score of moderate\/high density and Lewy body (LB) Braak &gt;0\u2009or cortical\/limbic\/neocortical LB pathology) or \u2018not significant\u2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ARB group was less likely to have Alzheimer\u2019s disease (AD) pathology compared with the ACEI group: Thal amyloid (adjusted OR (AOR) 0.59 (95%\u2009CI 0.36 to 0.97), p=0.038), Braak neurofibrillary tangle (AOR 0.61 (95%\u2009CI 0.38 to 0.98), p=0.041) and CERAD neuritic plaque (AOR 0.58 (95%\u2009CI 0.35 to 0.96), p=0.035). LB pathology did not differ significantly between ARB and ACEI groups, though use of either ACEI or ARB was associated with a lower likelihood of LB pathology (AOR 0.27 (95%\u2009CI 0.21 to 0.36), p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ARB use is associated with a lower risk of AD pathology. The association between ARB\/ACEI use and LB pathology requires further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001342","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:05:34Z","timestamp":1775750734000},"page":"e001342","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Association between angiotensin receptor blocker use and postmortem dementia pathology: analysis of the UK Brain Banks Network dataset"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0205-7273","authenticated-orcid":false,"given":"Muzuki","family":"Ueda","sequence":"first","affiliation":[{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Erskine","sequence":"additional","affiliation":[{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Thomas","sequence":"additional","affiliation":[{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calum","family":"Hamilton","sequence":"additional","affiliation":[{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C","family":"Donaghy","sequence":"additional","affiliation":[{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2026051208154145000_8.1.e001342.1","first-page":"00249","article-title":"Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"PMCID","year":"2019","journal-title":"Lancet Public Health"},{"key":"2026051208154145000_8.1.e001342.2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.14993"},{"key":"2026051208154145000_8.1.e001342.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11906-023-01266-0","article-title":"Angiotensin Receptor Blockers and Cognition: a Scoping Review","volume":"26","author":"Zhou","year":"2024","journal-title":"Curr Hypertens Rep"},{"key":"2026051208154145000_8.1.e001342.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105378","article-title":"Association between risk of Alzheimer\u2019s disease and related dementias and angiotensin receptor \u2161 blockers treatment for individuals with hypertension in high-volume claims data","volume":"109","author":"Lundin","year":"2024","journal-title":"EBioMedicine"},{"key":"2026051208154145000_8.1.e001342.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.10.019"},{"key":"2026051208154145000_8.1.e001342.6","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.1010"},{"key":"2026051208154145000_8.1.e001342.7","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.14283\/jpad.2024.156","article-title":"Anti-Hypertensives Reduce the Rate of Alzheimer\u2019s Disease Progression: A Cohort Study Linked with Genetic and Neuropathological Analyses","volume":"11","author":"Sternberg","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"2026051208154145000_8.1.e001342.8","unstructured":"UK Brain Banks Network . UK brain banks network. 2025. Available: https:\/\/ukbbn.brainsfordementiaresearch.org\/public\/en\/"},{"key":"2026051208154145000_8.1.e001342.9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12264-018-0327-2","article-title":"Brains for Dementia Research: The Importance of Cohorts in Brain Banking","volume":"35","author":"Francis","year":"2019","journal-title":"Neurosci Bull"},{"key":"2026051208154145000_8.1.e001342.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02255-2"},{"key":"2026051208154145000_8.1.e001342.11","first-page":"e2068","article-title":"Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study","volume":"101","author":"Romanowska","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2026051208154145000_8.1.e001342.12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1212\/WNL.0000000000002102","article-title":"Parkinson disease and incidental Lewy body disease: Just a question of time?","volume":"85","author":"Iacono","year":"2015","journal-title":"Neurology (ECronicon)"},{"key":"2026051208154145000_8.1.e001342.13","article-title":"A Comparative Study of the Safety and Efficacy Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Management of Hypertension: A Systematic Review","volume":"16","author":"Peresuodei","year":"2024","journal-title":"Cureus"},{"key":"2026051208154145000_8.1.e001342.14","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00740-0","article-title":"The association of APOE \u03b54 with cognitive function over the adult life course and incidence of dementia: 20\u2009years follow-up of the Whitehall II study","volume":"13","author":"Gharbi-Meliani","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2026051208154145000_8.1.e001342.15","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00778-8","article-title":"The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer\u2019s disease: the importance of blood-brain barrier penetration and APOE \u03b54 carrier status","volume":"13","author":"Ouk","year":"2021","journal-title":"Alzheimers Res Ther"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:17:00Z","timestamp":1778599020000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2025-001342"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001342","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}